Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association
This compound is part of our Longevity & Cellular Aging research category, which includes a range of laboratory-grade peptide compounds studied in controlled environments
In the long term, these drugs could help reduce the prevalence of obesity-related conditions, decreasing the burden on healthcare systems and improving the quality of life for millions globally
Obesity Clinical Development Pipeline Weight Loss Will early data shown by Lillys Triple G retatrutide (Phase 3) and Amgens AMG-133 (Phase 2) be recapitulated in ongoing studies to demonstrate both faster weight loss and greater total weight loss, compared to approved GLP-1 RA
Their use in non-diabetics has risen by a staggering 700% in the US between 2019 and 2023.2 Despite its popularity, barriers exist high costs, limited supply, and lack of a structured multidisciplinary obesity programs make their use challenging for many patients
However, that could change as more high-profile celebrities go public about their usage of the medications